Novartis (NVS)
(Delayed Data from NYSE)
$113.77 USD
-0.09 (-0.08%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $113.76 -0.01 (-0.01%) 5:12 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.77 USD
-0.09 (-0.08%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $113.76 -0.01 (-0.01%) 5:12 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
Incyte's (INCY) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.
Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod
by Kinjel Shah
Novartis (NVS) and Merck (MRK) announce Q3 results. FDA approves J&J's (JNJ) multiple myeloma candidate, Tecvayli.
Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.
Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.
What's in Store for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.
Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion
by Zacks Equity Research
Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.
Novartis (NVS) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novartis (NVS) closed at $75.57, marking a -0.58% move from the previous day.
Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv
by Zacks Equity Research
Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.
Merck (MRK) Posts Positive Results From PAH Drug Study
by Zacks Equity Research
Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.
Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?
by Zacks Equity Research
Gilead (GILD) is having a good run despite the volatility on a string of positive updates.
GSK's (GSK) Boostrix Gets FDA Nod for Pertussis in Newborns
by Zacks Equity Research
Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.
BioMarin (BMRN) Starts Restructuring Moves to Increase Efficiency
by Zacks Equity Research
BioMarin (BMRN) intends to reduce the existing workforce by nearly 4%. The company plans to use the savings in costs and redirect them toward its operating expenses.
Lilly's (LLY) Diabetes Drug Gets FDA Fast Track Tag for Obesity
by Zacks Equity Research
Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.
The Zacks Analyst Blog Highlights Novartis, Lowe's, The Goldman Sachs, Twitter and Xcel Energy
by Zacks Equity Research
Novartis, Lowe's, The Goldman Sachs, Twitter and Xcel Energy are part of the Zacks top Analyst Blog.
Top Research Reports for Novartis, Lowe's & Goldman Sachs
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Novartis AG (NVS), Lowe's Companies, Inc. (LOW) and The Goldman Sachs Group, Inc. (GS).
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal
by Zacks Equity Research
GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.
Biohaven (BHVN) Stock Up on Spin-Off Transaction Finalization
by Zacks Equity Research
The newly spun-off Biohaven Ltd. (BHVN) advances a portfolio of non-CGRP pipelines targeting neurological and neuropsychiatric indications.
Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?
by Zacks Equity Research
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.
NVS vs. RHHBY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVS vs. RHHBY: Which Stock Is the Better Value Option?
Is Novartis (NVS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III
by Zacks Equity Research
Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.
Novartis (NVS) to Focus on US Markets Backed by 8 Key Drugs
by Zacks Equity Research
Novartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight key brands that are expected to have a multi-billion dollar peak sales potential.
Strength Seen in Lilly (LLY): Can Its 4.9% Jump Turn into More Strength?
by Zacks Equity Research
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Novartis (NVS) to Appeal to Supreme Court for Gilenya Patent
by Zacks Equity Research
Novartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a petition in the Supreme Court after an unfavorable ruling in the federal court.